CD55 antibody (PE-Cy7)
Quick Overview for CD55 antibody (PE-Cy7) (ABIN2659538)
Target
See all CD55 AntibodiesReactivity
Host
Clonality
Conjugate
Application
Clone
-
-
Purification
- The antibody was purified by affinity chromatography, and conjugated with PE/Cy7 under optimal conditions. The solution is free of unconjugated PE/Cy7 and unconjugated antibody.
-
Isotype
- IgG1 kappa
-
-
-
-
Application Notes
- Optimal working dilution should be determined by the investigator.
-
Restrictions
- For Research Use only
-
-
-
Buffer
- Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide and 0.2 % (w/v) BSA .
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Handling Advice
- Protect from prolonged exposure to light. Do not freeze.
-
Storage
- 4 °C
-
Storage Comment
- The antibody solution should be stored undiluted between 2°C and 8°C.
-
-
- CD55 (Complement Decay-Accelerating Factor (CD55))
-
Alternative Name
- CD55
-
Background
- CD55 is a 60-70 kD glycosylphosphatidylinositol (GPI)-anchored single chain glycoprotein also known as decay-accelerating factor (DAF). It is expressed on hematopoietic cells including erythrocytes and many non-hematopoietic cells. CD55 accelerates the dissociation of the components of the C3-convertases (namely C2a from C4b in the C4bC2a complex, a C3-convertase of the classical pathway, and factor Bb from the C3bBb complex, a C3-convertase of the alternative pathway) to protect cells from inappropriate damage caused by autologous complement. CD55 has been reported to reduce the efficiency of NK cell lysis and induce signal transduction in T cells. CD55 has also been shown to interact with CD97 and bind to Coxsackie and Echovirus.
-
Pathways
- Complement System, Regulation of Leukocyte Mediated Immunity
Target
-